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ttp://dx.doi.org/10.1016/j.ajpath.2013.02.030Neuroinﬂammation, through production of proinﬂammatory molecules and activated glial cells, is
implicated in Alzheimer’s disease (AD) pathogenesis. One such proinﬂammatory mediator is tumor
necrosis factor a (TNF-a), a multifunctional cytokine produced in excess and associated with amyloid
bedriven inﬂammation and cognitive decline. Long-term global inhibition of TNF receptor type I
(TNF-RI) and TNF-RII signaling without cell or stage speciﬁcity in triple-transgenic AD mice exacerbates
hallmark amyloid and neuroﬁbrillary tangle pathology. These observations revealed that long-term pan
antieTNF-a inhibition accelerates disease, cautions against long-term use of antieTNF-a therapeutics
for AD, and urges more selective regulation of TNF signaling. We used adeno-associated virus vectore
delivered siRNAs to selectively knock down neuronal TNF-R signaling. We demonstrate divergent roles
for neuronal TNF-RI and TNF-RII where loss of opposing TNF-RII leads to TNF-RIemediated exacerbation
of amyloid b and Tau pathology in aged triple-transgenic AD mice. Dampening of TNF-RII or TNF-RIþRII
leads to a stage-independent increase in Iba-1epositive microglial staining, implying that neuronal
TNF-RII may act nonautonomously on the microglial cell population. These results reveal that TNF-R
signaling is complex, and it is unlikely that all cells and both receptors will respond positively to broad
antieTNF-a treatments at various stages of disease. In aggregate, these data further support the
development of cell-, stage-, and/or receptor-speciﬁc antieTNF-a therapeutics for AD. (Am J Pathol
2013, 182: 2285e2297; http://dx.doi.org/10.1016/j.ajpath.2013.02.030)Supported by NIH grants F31-AG038063 (S.L.M.), RO1-AG030149
(M.K.O.), and R01-AG023593 and R01-AG026328 (W.J.B.).
Current address of W.J.B., Vaccinex, Inc., Rochester, NY.Alzheimer’s disease (AD) pathophysiology is described by
chronic and progressive neurodegeneration involving the
genesis of extracellular amyloid b (Ab) plaques, intra-
neuronal ﬁlamentous inclusions called neuroﬁbrillary tan-
gles (NFTs), synapse loss, inﬂammation, and neuronal cell
death, ultimately leading to severe memory loss and cog-
nitive impairment. Neuroinﬂammation is a highly enigmaticstigative Pathology.
.process contributing to disease pathogenesis in AD, where
elevated levels of proinﬂammatory molecules have been
associated with Ab-induced inﬂammation, neurotoxicity,
Montgomery et aland cognitive decline.1e4 In AD-afﬂicted brains, microglia
intimately co-localize with Ab plaques and serve as major
sources of proinﬂammatory mediators, including cytokines
and chemokines.5 The pleiotropic proinﬂammatory cytokine
tumor necrosis factor a (TNF-a) is produced in excess
concurrently with increased Ab plaque deposition, an ob-
servation that suggests that TNF-a levels reﬂect the path-
ologic progression of AD.6e8 Moreover, three TNF-a
promoter polymorphisms have been associated with late-
onset AD, and two of the three polymorphisms are linked
to increased TNF-a production, further connecting this
cytokine to the exacerbated chronic inﬂammatory disease
status in AD.9 We and others have demonstrated that TNF-a
expression is enhanced in AD mouse models where TNF-a
is prepathologically up-regulated in 6-month-old triple-
transgenic AD (3xTg-AD) mice,10,11 which corresponds
with an enhancement of F4/80-positive microglial cell
numbers.12 In addition, when neuron-speciﬁc TNF-a is
chronically overexpressed in 3xTg-AD mice using adeno-
associated virus (AAV) vectors, there is increased severity
of inﬂammation, intracellular Ab, and Tau pathology that
leads to neuronal cell death portending that excessive and
unopposed TNF-a signaling enhances AD-associated
pathology and is detrimental to neuronal viability.13
TNF-a signals through two cognate transmembrane
receptors, TNF receptor type I (TNF-RI) and TNF-RII,
which are differentially expressed and regulated. TNF-RI is
expressed constitutively on most cell types, whereas
TNF-RII expression is induced and is restricted to speciﬁc
cell populations, including hematopoietic cells, microglia,
neurons, and endothelial cells.14,15 TNF-R engagement to its
ligand mediates distinct cellular responses through the ac-
tivation of several downstream signal transduction cascades
involving the NFkB and JNK pathways. In the context of
AD, several reports demonstrate differential roles and acti-
vation of TNF-RI and TNF-RII such that genetic deletion of
TNF-RI, but not TNF-RII, results in reduced plaque depo-
sition in the APP23 mouse model.16 Moreover, in human
brain tissue, TNF-RI protein levels are increased, whereas
TNF-RII levels are reduced in patients with AD relative to
nondemented control brain.17 Taken together, these data
imply an overall negative role for excessive TNF signaling
on AD pathophysiology but, perhaps more importantly,
illustrate the complexity of this signaling pathway.
Despite a large body of literature indicating detrimental
roles for TNF-a, neuroprotective effects have also been re-
ported. Early experiments revealed that TNF-a is protective
in cultured neurons during glucose deprivationeinduced
injury and excitotoxicity by preserving Ca2þ homeostasis.18
Barger et al19 further demonstrated in dissociated neuronal
cultures that pretreatment with TNF-a and Ab peptide spares
cells from Ab-induced neuronal death, iron toxicity, and
intracellular Ca2þ accumulation via an NF-kBedependent
mechanism. Moreover, neurons are vulnerable to ischemic
injury and oxidative stress in TNF-R null mice, indicating
that TNF-a is protective.20 Mice lacking TNF-R expression2286exhibited reduced manganese superoxide dismutase activity
and lacked a robust microglial response to kainic acid.20
Similarly, cultured neurons pretreated with TNF-a resulted
in a signiﬁcant increase in manganese superoxide dismutase
activity and a reduction in superoxide accumulation.21 These
data add to the complexity of the TNF signaling pathway and
suggest that strategies to modulate TNF-a in the disease
setting may require selective tuning and speciﬁcity to ensure
that protective signaling outcomes are not compromised.
Nonetheless, given the compelling data supporting the
pathologic role of TNF-a in AD, the potential of using
antieTNF-a therapeutics has become a viable strategy for
subverting the disease course. Preclinical data by McAlpine
et al22 demonstrate that transiently inhibiting soluble TNF
signaling in the 3xTg-AD mouse model using a dominant-
negative inhibitor in conjunction with enhanced systemic
inﬂammation prevents AD-associated amyloid pathology.
Tobinick et al23 reported in a short-term, prospective, open-
label pilot study that semiweekly perispinal administration
of etanercept, a receptor decoy biological agent antagonizing
the actions of TNF-a, in 15 patients with mild to severe AD
led to signiﬁcant and rapid cognitive improvements
compared with untreated control patients as assessed by
three separate tests measuring cognitive function.
Although previous studies provide evidence suggesting
that TNF-a inhibition in the short-term may lead to
improved pathologic and functional outcomes, they lack
data addressing the long-term consequences of blocking
TNF-a in a global manner, where cell, stage, and receptor
speciﬁcity were not examined. To this end, we recently
demonstrated that long-term global inhibition of TNF-R
signaling in 3xTg-AD mice where TNF-RI and TNF-RII
were ablated in all cell types results in a robust increase in
hallmark amyloid and NFT pathology. Furthermore, in the
absence of TNF signaling, microglia seem nonresponsive to
the developing amyloid pathology, which correlates with an
impairment of microglial-mediated Ab42 phagocytosis
activity in vitro.24 These data suggest that caution should be
taken with the use of broad long-term anti-TNF inhibitors
and that a more selective strategy should be investigated.
Toadd to our understandingofTNFsignalingbiologyand the
consequences of selectively modulating this pathway, we
investigated the cell- and stage-speciﬁc role of TNF-R signaling
in AD by using recombinant AAV (rAAV) vectoredelivered
siRNA technology to selectively knock down neuronal TNF-R
signaling at stages preceding progressive pathology or in the
presenceof extant diseaseusing the3xTg-ADmousemodel.We
demonstrate that neuronal TNF-RI and TNF-RII exert differ-
ential actions where intact TNF-RII signaling results in sup-
pressed Ab plaque deposition and paired helical ﬁlament (PHF)
formation in the context of progressive and established disease
pathogenesis. In addition, we report a substantial reduction in
Iba-1epositive microglia when rAAV2-delivered siTNF-RII or
siTNF-RIþRII viral vectors are administered at 2 and12months
of age. Taken together, these data demonstrate that selectively
suppressing neuronal TNF-RI and/or TNF-RII leads to distinctajp.amjpathol.org - The American Journal of Pathology
TNF Receptor Ablation in 3xTg-AD Miceand signiﬁcant changes in AD pathogenesis, which is most
likely a consequence of the divergent signaling pathways
associated with these receptors. The present ﬁndings support
further development and rigorous study of highly selective
strategies designed to inhibit speciﬁc TNF-aemediated signals
and potentially disrupt the onset and/or progression of this
debilitating disease.
Materials and Methods
Design, Veriﬁcation, and Packaging of siTNF-RIe,
siTNF-RIIe, and siScr-Expressing rAAV2 Vectors
Using the siRNA Wizard algorithm (InvivoGen, San Diego,
CA), target sequences for siRNA-mediated gene silencing
were generated for TNF-RI and TNF-RII mRNA based on the
following GenBank accession numbers: NM_011609 for
TNF-RI and NM_011610 for TNF-RII. A scrambled control
(Scr) sequence was also designed that lacked speciﬁcity to any
mouse gene and served as a nonspeciﬁc negative control for
subsequent experiments. Using the selected sequences,
oligonucleotide pairs were designed to create a hairpin insert
for plasmid siRNA (psiRNA)e7SKneo cloning vectors
(InvivoGen). The RNA Pol III 7SK promoter and oligo-
nucleotide sequence targeting each gene of interest were
excised using the ClaI and XbaI restriction sites from the
three custom-made psiRNA plasmids denoted as psiR-
NAe7SKneoemTNF-RI, psiRNAe7SKneoemTNF-RII,
and psiRNA-7SKneo-mScr and cloned into the pBluescript
II KSþ (pFBIIKSþ) plasmid harboring a cytomegalovirus
(CMV) promoter driving the expression of enhanced green
ﬂuorescent protein (eGFP) in the reverse orientation. This
yielded intermediate plasmids containing a dual promoter
system where the 7SK siRNA promoter drove the expres-
sion of siTNF-RI, siTNF-RII, and siScr, whereas in the
opposite orientation, the CMV immediate-early promoter
controlled eGFP expression. The resultant plasmids were
designated pFBIIKSþ(CMVeGFP rev)(7SK-mTNF-RI for),
pFBIIKSþ(CMVeGFP rev)(7SK-mTNFR-II for), and
pFBIIKSþ(CMVeGFP rev)(7SK-mTNF-R Scr for). The
7SK-siRNA and CMVeGFP transcriptional units were
removed via NotI restriction digestion and were subcl-
oned into a modiﬁed inverted terminal repeatecontaining
pFBGR plasmid lacking the eGFP gene (Figure 1A). The
pFBGR(CMVeGFP rev)(mTNF-RI for), pFBGR(CMVeGFP
rev)(mTNF-RII for), and pFBGR(CMVeGFP rev) (mTNFR
Scr. for) plasmids were tested in vitro via transient trans-
fection into baby hamster kidney (BHK) 21 cells. Knock-
down efﬁciency was assessed by immunocytochemical
analysis (Figure 1, BeQ) before packaging into serotype 2
AAV virions using a baculovirus-based procedure.25
Cell Transfections
BHK21 cells were plated at 5 104 cells per well in a poly-D-
lysineecoated 24-well culture dish for immunocytochemicalThe American Journal of Pathology - ajp.amjpathol.organalysis. Transfections were performed using Lipofectamine
2000 (Life Technologies, Grand Island, NY) at equimolar
quantities of plasmid: pFBGR-siScr þ TNF-RI, pFBGR-
siScr þ TNF-RII, pFBGR-siTNF-RI þ TNF-RI, or
pFBGReTNF-RII þ TNF-RII cDNA. Cells were incubated
with Opti-MEM (Life Technologies) serum-free media
containing Lipofectamine and plasmid DNA for 5 hours at
37C. Next, transfection medium was removed, and Dul-
becco’s modiﬁed Eagle’s mediumþ 10% fetal bovine serum
growth medium was added to the cells. Cells were ﬁxed with
4% paraformaldehyde 48 hours after transduction.
Fluorescence Immunocytochemical Analysis
Paraformaldehyde-ﬁxed cells were blocked with 10% normal
goat serum in 1x Tris-buffered saline for 1 hour at room
temperature. TNF-RI/RII expression was detected with
polyclonal rabbit TNF-RI or TNF-RII primary antibodies
(dilution 1:250; Abcam Inc., Cambridge, MA) in conjunction
with Alexa Fluor 568 (dilution 1:200; Life Technologies,
Grand Island, NY), whereas eGFP epiﬂuorescence was used
to determine transfection efﬁciency. Images were visualized
via ﬂuorescence microscopy at 20 magniﬁcation.
Transgenic Mice
3xTg-AD mice of the B1 line were a gift from Dr. Frank
LaFerla (University of California, Irvine, CA).10,11 Homozy-
gous 3xTg-AD male mice were stereotactically injected
with rAAV2 vectors using convection-enhanced delivery
and were subsequently analyzed by immunohistochemical
(IHC)/quantitative assessment studies (n Z 6 per experi-
mental group) or biochemical assays (nZ 4 to 6). Mice were
euthanized at 15 or 21 months of age. For IHC experiments,
mice were sacriﬁced using pentobarbital overdose, followed
by transcardiac perfusion with heparinized saline, followed by
4% paraformaldehyde in 0.1 mol/L phosphate buffer. Brains
were then sequentially transferred to 20% sucrose in 0.1mol/L
PBS overnight and 30% sucrose in 0.1 mol/L PBS. Next,
30-mm-thick sections were processed using a freezing stage
microtome (Microm International, Walldorf, Germany) and
were stored at 20C in cryoprotectant until further use. For
biochemical analyses, brains were microdissected from
a separate cohort of mice to generate protein and RNA
samples. Animal housing and procedures were performed in
compliancewithNIHGuidelines forAnimalCare andUse and
were approved by the University Committee of Animal
Resources at the University of Rochester (Rochester, NY).
Mice were on a 12-hour light-dark cycle in a climate-
controlled facility andwere allowed food andwater ad libitum.
Stereotactic Injections by Convection-Enhanced
Delivery of rAAV2-siRNAs
3xTg-AD male mice, 2 and 12 months old, stereotactically
received bilateral hippocampal injections via convection-2287
Figure 1 Construction and in vitro character-
ization of three rAAV vectors expressing siTNF-RI,
siTNF-RII, or siScr. A: Schematic depicting
a dual-promoter system of the rAAV2 constructs
under the transcriptional regulation of the 7SK
RNA polymerase III promoter encoding for siTNF-
RI, siTNF-RII, or siScr and eGFP under the tran-
scriptional control of the CMV immediate-early
promoter in the reverse orientation. ITR, inverted
terminal repeat. Before AAV2 packaging, BHK cells
were transiently cotransfected with the pFBGR
shuttle vector plasmids containing TNF-RI (BeI) or
TNF-RII (JeQ) cDNA and the siTNF-RI (FeI),
siTNF-RII (NeQ), or siScr (BeE and JeM)
sequences. Cells were harvested 48 hours after
transfection, and in vitro expression and receptor
knockdown efﬁciency were assessed via IHC anal-
ysis using epiﬂuorescence eGFP (C, G, K, and O)
and mouse antieTNF-RI (D and H) or mouse antie
TNF-RII (L and P) in conjunction with an Alexa
Fluor 568 ﬂuorescent secondary antibody (D, H, L,
and P) for receptor expression detection. Bright
ﬁeld images were acquired at 20 magniﬁcation
(B, F, J, and N), and E, I, M, and Q represent
merged eGFP and Alexa Fluor 568 signals. Scale
bar Z 200 mm.
Montgomery et alenhanced delivery using rAAV2-siScr, rAAV2esiTNF-RI,
rAAV2esiTNF-RII, or an equal viral load of rAAV2e
siTNF-RIþRII capsids in accordance with approved
University of Rochester animal use guidelines as previously
described.26 Brieﬂy, under Avertin anesthesia (300 mg/kg)
(Sigma-Aldrich, St. Louis, MO), mice were placed in
a stereotactic apparatus, the skull was exposed, and two burr
holes were drilled bilaterally at designated hippocampal
coordinates (bregma position 2.06 mm, 1.5 mm laterally,
1.25 mm ventrally). Injections were performed using
a microprocessor-controlled pump (UltraMicroPump; World
Precision Instruments, Sarasota, FL) and a 33-gauge needle
(Hamilton Co., Reno, NV) that was gradually lowered into the
parenchyma to the desired depth. A total of 5 mL of each
rAAV2-siRNA vector (2  109 transduction units)
was continuously injected by increasing delivery rates at
100 nL/min for 6 minutes, 200 nL/min for 10 minutes, and
400 nL/min for 6minutes into both hemispheres. Subsequent to
both injections, incisions were closed via Vicryl sutures (Ethi-
con Inc., a Johnson& Johnson company, Somerville, NJ), a 5%
lidocaine topical ointment (Fougera Pharmaceuticals Inc.,
a Sandoz company, Melville, NY) was applied, and the mice
were placed into a heated recovery chamber to recuperate.
Primary Antibodies
The following antibodies and their respective dilutions were
used to IHC stain coronal sections of 15- and 21-month-old
3xTg-AD mice: anti-Ab 1-42 clone 12F4 reactive to the2288C-terminus of b-amyloid speciﬁc for the isoform ending at
amino acid 42 (dilution 1:1000; Signet Laboratories, Ber-
keley, CA); microglia/macrophage-speciﬁc cell marker
[anti-ionized calcium-binding adaptor molecule (Iba-1)],
rabbit polyclonal (dilution 1:750; Wako Chemicals USA
Inc., Richmond, VA); astrocyte-speciﬁc cell marker [poly-
clonal rabbit anti-glial ﬁbrillary acidic protein (GFAP)]
(dilution 1:1000; Dako North America, Carpinteria, CA);
PHF-1 recognizing singly or doubly phosphorylated Tau at
Ser396 and/or Ser404 residues (dilution 1:30; a gift from Dr.
Peter Davies, Albert Einstein College of Medicine, Bronx,
NY); rabbit anti-GFP (dilution 1:750; Life Technologies);
monoclonal anti-NeuN, clone A60, biotin conjugated (dil-
ution 1:300; Chemicon, Billerica, MA); and monoclonal
anti-GFAPeCy3, conjugated (dilution 1:1000; Sigma-
Aldrich, St. Louis, MO).
IHC Analyses
Cryoprotectant was removed from brain sections by washing
with 0.15 mol/L phosphate buffer, and endogenous peroxi-
dase activity was quenched with 3% H2O2 in 0.15 mol/L
phosphate buffer. For Ab peptideespeciﬁc stains, epitope
retrieval was performed using 70% formic acid for 15
minutes. Diaminobenzidine IHC analysis was performed as
previously described.27 Images from the CA1 and subiculum
subregions of the hippocampal formation between bregma
positions 4.20 mm and 1.82 mm were acquired under
20magniﬁcation, and staining intensities were quantiﬁed inajp.amjpathol.org - The American Journal of Pathology
TNF Receptor Ablation in 3xTg-AD Micea blinded manner above a preset threshold using the MCID
Elite, version 6.0, imaging software program (InterFocus
Imaging, a subsidiary of GE Healthcare, Cambridge,
England). The average number of pixels per unit area from at
least four sections per slide per mouse were analyzed (4 to 6
images for the subiculum and 16 to 20 images for the CA1
region), and the means were statistically assessed (nZ 6 per
injection condition). Representative light microscopic images
at 10 magniﬁcation were acquired for each immunohisto-
logic experiment using a Zeiss Axioplan IIi microscope (Carl
Zeiss, Oberkochen, Germany) equipped with a Spot RT
camera and software (version 4.5.9.8; Diagnostic Ins-
truments, Burroughs, MI).
Fluorescence Co-IHC Analysis
Coronal brain sections from 15-month-old 3xTg-AD mice
receiving bilateral hippocampal injections with the rAAV2-
siScr vector were processed for ﬂuorescence co-IHC anal-
ysis to demonstrate neuronal targeting of serotype 2 viral
capsids. Tissue sections were washed in PBS to remove
cryoprotectant and were permeabilized for 5 minutes with
PBS þ 0.4% Triton X-100 (Roche Diagnostics GmbH,
Mannheim, Germany), followed by blocking with PBS þ
0.4% Triton X-100 þ 10% normal goat serum for 1 hour.
Three separate co-IHC analyses were performed using
rabbit anti-GFP and monoclonal anti-NeuN, rabbit anti-GFP
and rabbit polyclonal antieIba-1, or rabbit anti-GFP and
monoclonal anti-GFAPeCy3 antibodies diluted in PBS þ
0.4% Triton X-100 þ 1% normal goat serum (refer to
Primary Antibodies for the speciﬁc dilutions used) and
incubated overnight at 4C. Subsequently, sections were
washed 3  10 minutes in PBS þ 0.4% Triton X-100 þ 1%
normal goat serum and were incubated for 2 hours with goat
anti-rabbit Alexa Fluor 488 secondary antibody to detect
anti-GFP and goat anti-mouse or goat anti-rabbit Alexa
Fluor 568 (dilution 1:1000; Life Technologies), secondary
antibody to detect anti-NeuN or antieIba-1, respectively,
and then were washed in PBS 3  10 minutes. Sections
were mounted and coverslipped with Mowiol medium
(Sigma-Aldrich). Images were captured with equal exposure
times at 20 using an AttoArc 2 mercury lamp (Carl Zeiss),
an Axioplan IIi microscope equipped with a SensiCam QE
camera (The Cooke Corp., Auburn Hills, MI), and Slide-
Book 5.0 imaging software version 5.0.08 on Windows XP
(Intelligent Imaging Innovations Inc., Denver, CO).
Enzyme-Linked Immunosorbent Assay
Hippocampal tissue was microdissected from transduced
15- and 21-month-old 3xTg-AD mice, followed by storage
at 80C. Frozen tissue was weighed, homogenized, and
fractionated by ultracentrifugation. Hippocampal tissue ho-
mogenates were assessed for levels of insoluble Ab40 and
Ab42, as previously described.
26 A portion of the soluble
tissue fraction was used to analyze mouse TNF-a proteinThe American Journal of Pathology - ajp.amjpathol.orglevels using a ready-to-use enzyme-linked immunosorbent
assay (ELISA) kit (Life Technologies). Samples were
diluted 1:5, and the assay was run per the manufacturer’s
protocol; total protein was assayed by OD measurement at
450 nm.
Imaging and Image Processing
Photomicrographs were processed consistently where bright-
ness and contrast were applied identically over all the images
in an experimental data set using Photoshop CS3 version
10.0.1 (Adobe Systems Inc., San Jose, CA). No other image-
processing manipulations were performed except for pho-
tomicrographs containing digitally magniﬁed inset images to
highlight cellular morphology.
Statistical Analyses
Statistical analyses were performed using GraphPad Prism
version 5 software (GraphPad Software Inc., San Diego,
CA) by means of one-way analysis of variance followed by
Bonferroni’s posttest. Figure legends and results sections
specify each statistical test used and associated P values for
each experiment.Results
rAAV2-Mediates RNA Interference Knockdown of
TNF-RI and TNF-RII in Vitro
Three rAAV2 vectors (Figure 1A) were designed to
express both eGFP under the regulatory control of the
CMV immediate-early promoter, allowing for visualization
of vector-transduced cells, and a 7SK RNA polymerase III
promoteredriven siRNA.28 Before rAAV2 packaging, the
pFBGR shuttle vectors harboring siTNF-RI, siTNF-RII, or
siScr were tested in vitro via transient cotransfection of
BHK cells with respective TNF-RI or TNF-RII cDNA-
encoding plasmids (Figure 1, BeQ). Forty-eight hours
after transfection, BHK cells were processed and evaluated
for eGFP and TNF-RI or TNF-RII expression by ﬂuores-
cence co-IHC analysis. We observed a marked reduction in
TNF-RI expression (mean  SD: 78.9%  1.520%) in
BHK cells cotransfected with siTNF-RI and TNF-RI
plasmids (Figure 1, H and I), whereas BHK cells re-
ceiving siScr control plasmid and TNF-RI plasmid retained
TNF-RI expression (Figure 1, D and E). Similarly, cells
cotransfected with siTNF-RII and TNF-RII plasmids
demonstrated a substantial reduction in TNF-RII expres-
sion (mean  SD: 78.8%  2.115%) (Figure 1, P and Q)
compared with cells transfected with siScr plasmid
(Figure 1, L and M). These data indicated that the con-
structed rAAV2 vectors were selective and effective at
knocking down TNF-RI or TNF-RII expression in vitro
and that they were subsequently packaged into rAAV2
capsids.2289
Figure 2 rAAV2-expressing siRNA vectors selec-
tively targetedpyramidal neurons of the CA1 sublayer.
A: The schematic diagram illustrates the experimental
design of 3xTg-AD mice receiving stereotactic bilat-
eral hippocampal infusions of rAAV2at 2 or 12months
and harvested at 15 or 21 months, respectively.
Coronally sectioned 15-month-old rAAV2-siScre
injected tissue was co-immunostained with an anti-
eGFP primary antibody in conjunction with anti-
NeuN (neurons) (BeD), anti-GFAP (astrocytes)
(EeG), or antieIba-1 (microglia) (HeJ) to localize
eGFP-positive cells. Boxed areas are shown as insets
at a higher magniﬁcation. Scale barZ 500 mm.
Montgomery et alrAAV2-Expressing siRNA Vectors Selectively Target
Pyramidal Neurons of the CA1 Sublayer in Vivo
We next aimed to determine whether the functional siRNA-
expressing viral plasmids packaged into rAAV2 virions
were neuronally selective when delivered stereotactically to
the mouse brain. To this end, 2- and 12 month-old 3xTg-AD
mice, which develop AD-related amyloid and Tau pathol-
ogies,10,11 received stereotactic bilateral hippocampal
injections of rAAV2-siScr, rAAV2esiTNF-RI, rAAV2e
siTNF-RII, or rAAV2esiTNF-RIþRII and were aged to 15
and 21 months, respectively (Figure 2A). To ensure that
in vivo rAAV2 transduction selectively targeted the
neuronal cell population, we ﬂuorescently colabeled coro-
nally sectioned 15-month-old 3xTg-AD brain tissue trans-
duced with rAAV2-siScr using anti-eGFP plus anti-NeuN,
anti-GFAP, or antieIba-1 primary antibodies and performed
immunoﬂuorescence microscopy to localize eGFP-positive
cells (Figure 2, BeJ). On microscopic visualization, it was
demonstrated that eGFP expression speciﬁcally colo-
calized with NeuN-positive cells (Figure 2, BeD), hence
conﬁrming that the rAAV2 vectors were selectively trans-
ducing neurons and expressing the eGFP reporter gene
product in vivo. Neither astrocytes nor microglial cells were2290transduced as assessed by colabeling for GFP and anti-
GFAP (Figure 2, EeG) or antieIba-1 (Figure 2, HeJ),
respectively.
In Vivo rAAV2 Viral VectoreMediated Knockdown of
Neuronal TNF-RII in 3xTg-AD Mice Leads to
a Signiﬁcant Elevation in Extracellular Ab42 Plaque
Deposition at Later Stages of Disease
An accruing body of evidence suggests an intimate association
between TNF-a receptor signaling and Ab accumulation in the
setting of AD.6e8,29 To investigate the cell- and stage-speciﬁc
effect of neuronal knockdown of TNF-RI and/or TNF-RII
on Ab pathology, IHC analysis was performed. Coronal
brain sections of age-matched 15- and 21-month-old
mice bilaterally transduced with rAAV2-siScr, rAAV2e
siTNF-RI, rAAV2esiTNF-RII, or rAAV2esiTNF-RIþRII at
2 and 12 months, respectively, were immunostained with the
anti-12F4 antibody, which speciﬁcally detects extracellular
Ab42 deposits (Figure 3, AeH). Deposition in the hippo-
campal CA1 and subicular regions was subsequently as-
sessed by quantitative image analysis (Figure 3, IeL).
Representative hippocampal images at 10 magniﬁcation
are displayed for 3xTg-AD mice injected with rAAV2 at 2ajp.amjpathol.org - The American Journal of Pathology
Figure 3 In vivo rAAV2 viral vectoremediated
knockdown of neuronal TNF-RII in 3xTg-AD mice
led to a signiﬁcant elevation of extracellular Ab42
plaque deposition at later stages of disease.
Coronal brain sections from 15-month-old (AeD)
and 21-month-old (EeH) 3xTg-AD mice that
received bilateral hippocampal injections at 2 and
12 months of age, respectively, with rAAV2-siScr
(A and E), rAAV2esiTNF-RI (B and F), rAAV2e
siTNF-RII (C and G), or rAAV2esiTNF-RIþRII (D
and H) were IHC analyzed for extracellular Ab42
plaque deposition using a human Ab42-speciﬁc
antibody, 12F4, and were subjected to dia-
minobenzidine IHC analysis. Representative
images of the hippocampus were captured at 10
magniﬁcation (AeH). Scale bar Z 500 mm. The
staining intensities in the CA1 (I and K) and
subiculum (J and L) subregions for extracellular
Ab42-postive plaques were elucidated. Statistical
analyses were performed via one-way analysis of
variance and Bonferroni’s posttest. Error bars
represent SEM. n Z 6. *P < 0.0001.
TNF Receptor Ablation in 3xTg-AD Micemonths old (Figure 3, AeD) and 12 months old (Figure 3,
EeH). On image analysis, it was revealed that in earlier
stages of disease, when neuronal TNF-R expression was
suppressed starting at 2 months of age, extracellular plaque
deposition did not signiﬁcantly change in mice receiving
rAAV2esiTNF-RI, rAAV2esiTNF-RII, or rAAV2esiTNF-
RIþRII compared with that of age-matched rAAV2-siScre
injected 3xTg-AD mice (Figure 3, I and J). However,
knocking down TNF-RII starting at 12 months of age, which
represents an age when 3xTg-AD mice harbor appreciable
AD-associated pathology,27 leads to a striking and signiﬁcant
increase in 12F4-positive plaque deposition in the CA1
and subicular subregions of the hippocampus relative to
TNF-RI, TNF-RIþRII, or control vector knockdown cohorts
(Figure 3, K and L).
To further assess Ab pathology, we measured levels of
soluble and insoluble Ab40 and Ab42 peptide levels in the
brains of 3xTg-AD mice injected at 2 and 12 months by
ELISA (Figure 4). We observed a signiﬁcant elevation in
insoluble Ab42 levels in mice receiving neuronal rAAV2e
siTNF-RII at 2 (Figure 4F) and 12 (Figure 4H) months of
age and increased insoluble Ab40 levels at 12 months of age
(Figure 4G) compared with the rAAV2-siScr, rAAV2e
siTNF-RI, and rAAV2esiTNF-RIþRII cohorts. No signif-
icant differences were discernible for the soluble Ab40 and
Ab42 fractions in transduced 2- and 12-month-old 3xTg-AD
mice. Taken together, these data indicate that suppressing
neuronal TNF-RIIemediated signaling in the 3xTg-ADThe American Journal of Pathology - ajp.amjpathol.orgmouse at later stages of disease leads to marked Ab plaque
pathology.TNF-RII Knockdown in Neurons Via rAAV2 Viral Vector
Delivery at 12 Months of Age in 3xTg-AD Mice Robustly
Increases PHF Formation Compared with TNF-RI, TNF-
RIþRII, or Control Vector Knockdown
To examine the consequence of neuronal TNF-R knockdown
in 3xTg-AD mice on Tau-related pathology, we assessed
intracellular NFTs. Because we observed a dramatic effect on
extracellular Ab deposition in the later stages of disease, and
pathologic Ab peptides may directly or indirectly enhance the
formation of NFTs,30e32 we assessed PHF pathology. Using
the PHF-1 antibody, which recognizes singly or doubly
phosphorylated Ser396 and Ser404 epitopes, we immuno-
stained coronal brain sections of 21-month-old 3xTg-ADmice
transduced with rAAV2siScr, rAAV2esiTNF-RI, rAAV2e
siTNF-RII, or rAAV2esiTNF-RIþRII (Figure 5, AeD).
Quantitative image analysis demonstrated that rAAV2e
siTNF-RII delivery led to robust enhancement of PHF-1e
immunopositive staining intensity that was absent in mice
transduced with rAAV2-siScr, rAAV2esiTNF-RI, and
rAAVesiTNF-RIþRII (Figure 5E), indicating that the
suppression of onlyTNF-RII, but not TNF-RI orTNF-RIþRII,
affects the severity of amyloid (Figures3,EeH, J, andK, and4,
G and H) and NFT pathologies in the later stages of disease.2291
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Figure 4 Neuronal rAAV2esiTNF-RII delivery to 3xTg-ADmice injected at
12 months old led to a signiﬁcant increase in insoluble Ab40 and Ab42 levels.
Hippocampal tissue homogenates of 3xTg-AD mice injected at 2 months old
(A, B, E, and F) and 12 months old (C, D, G, and H) were subjected to soluble
(AeD) and insoluble (EeH) Ab40 (A, C, E, and G) and Ab42 (B, D, F, and H)
ELISA. One-way analysis of variance and Bonferroni’s posttest were per-
formed. Error bars denote SEM. n Z 3 to 4. *P < 0.05, **P < 0.001, and
***P < 0.0001.
Figure 5 TNF-RII knockdown in neurons via AAV2 viral vector delivery
at 12 months of age in 3xTg-AD mice robustly increased PHF formation
compared with TNF-RI, TNF-RIþRII, or control vector knockdown. AeD:
Coronal brain sections of 3xTg-AD mice bilaterally and hippocampally
transduced at 12 months of age were harvested at 21 months and subjected
to diaminobenzidine IHC analysis for PHF Tau (Ser396 and Ser404) using
the PHF-1 antibody. Representative 10 images are provided. Insets are
digitally enhanced 3 images of the designated immunostained CA1 region
to highlight cellular morphology. Scale bar Z 500 mm. E: Staining inten-
sities of PHF-1 immunoreactive cells were quantitated. One-way analysis of
variance and Bonferroni’s posttest were performed. Error bars represent
SEM. n Z 6. *P < 0.0001.
Montgomery et alSelective Neuronal TNF-RII or TNF-RIþRII Knockdown
Via AAV2-siRNA Transduction Leads to an Unexpected
Reduction in Iba-1ePositive Microglial Staining
Intensities
Microglia and astrocytes are highly plastic cells that interact
and react to changes in the central nervous system micro-
environment.33,34 Astrocytes are critical in brain homeo-
stasis and are metabolically coupled in many processes with
neurons, whereas microglia survey the brain parenchyma to
detect physiologic disturbances. Microglial activation is
partly controlled by neurons that produce or express a large
number of regulatory factors, and, often, loss of one or more
of these ligands results in the activation of microglia.35e38
Given the importance of neuron-microglia and neuron-
astrocyte interactions, we investigated the extrinsic role of
neuronal TNF-R signaling on microglia and astrocytes in
the setting of experimental AD. Coronal sections from
15- and 21-month-old 3xTg-AD mice that were bilaterally2292injected at 2 and 12 months of age, respectively, with
rAAV2-siScr, rAAV2esiTNF-RI, rAAV2esiTNF-RII, or
rAAV2esiTNF-RIþRII were IHC stained with the Iba-1
microglia/macrophage-speciﬁc marker (Figure 6) or the
GFAP (data not shown) to assess whether modulations in
neuronal TNF-R signaling alter microglial or astrocyte
marker expression. Unexpectedly, the staining intensities
of Iba-1epositive microglia in 15- and 21-month-old
3xTg-AD mice were signiﬁcantly reduced when TNF-RII or
TNF-RIþRII expression was suppressed (Figure 6, C, D,
GeJ). Knockdown of neuronal TNF-RI led to a signiﬁcantajp.amjpathol.org - The American Journal of Pathology
Figure 6 Selective neuronal TNF-RII or TNF-
RIþRII knockdown via rAAV2-siRNA transduction
led to an unexpected reduction in Iba-1epositive
microglial staining. Two- and twelve-month-old
3xTg-AD mice received bilateral hippocampal
injections of rAAV2-siScr, rAAV2esiTNF-RI, rAAV2e
siTNF-RII, or rAAV2esiTNF-RIþRII and were
euthanized at 15 and 21 months of age, respec-
tively. Coronal histologic sections were stained
with Iba-1 microglial-speciﬁc marker, followed by
diaminobenzidine IHC analysis. Representative
images at 10 magniﬁcation are shown (AeH),
and insets are digitally enhanced 4 images to
demonstrate cellular morphology. Scale barZ 500
mm. Iba-1epositive pixels were enumerated in the
CA1 region of the hippocampus for mice receiving
viral vectors at 2 and 12 months of age (I and J).
Statistical analyses performed included one-way
analysis of variance and Bonferroni’s posttest.
Error bars indicate SEM. n Z 6. *P < 0.05, **P <
0.001, and ***P < 0.0001.
TNF Receptor Ablation in 3xTg-AD Miceenhancement of Iba-1epositive microglia at 15 months of
age compared with age-matched control vectoreinjected
3xTg-AD mice (Figure 6I). The difference in Iba-1 staining
intensities between 15-month-old 3xTg-AD mice trans-
duced with rAAV2esiTNF-RI or rAAV2-siScr was not
observed in the cohort of mice transduced at a later stage of
disease (Figure 6J). The staining intensities of GFAP-
expressing astrocytes remained unaltered for all trans-
duction conditions (data not shown). In aggregate, these
data suggest that pathways regulated by neuronal TNF-RII
may be important in providing activation signals to local
microglia as AD-related pathology develops.
Neuronal TNF-R Modulation via siRNA Technology
Results in a Stage-Dependent Alteration of
Endogenous TNF-a Levels
An important consideration in this study is whether modu-
lating the expression of TNF-RI and TNF-RII affects
endogenous TNF-a levels. To that end, we performed a
mouse TNF-a sandwich ELISA using hippocampal protein
tissue homogenates from 15- and 21-month-old 3xTg-AD
mice transduced with the viral vector siRNA constructs at 2
and 12 months, respectively. In the 15-month-old cohort
(transduced at 2 months of age), we observed a signiﬁcant
increase in TNF-a levels in mice receiving rAAV2esiTNF-
RIþRII relative to the rAAV2-siScr control, suggesting that
when both targets of TNF-a are dampened, there is an
accumulation of soluble TNF-a (Figure 7A). TNF-R modu-
lation initiated during ongoing disease results in a different
TNF-a proﬁle. In the 21-month-old cohort (transduced at 12
months), there is a signiﬁcant reduction in TNF-a proteinThe American Journal of Pathology - ajp.amjpathol.orgexpression when TNF-RII or TNF-RIþRII is silenced in
neurons (Figure 7B). These observations indicate that
neuronal TNF-RII expression exerts differential effects on
total TNF-a protein levels in a temporal-dependent manner.Discussion
Studies have implicated long-term TNF-a up-regulation in
the progression of AD, but the purported function of this
immune modulator in disease remains unclear and intensely
debated. Given the pleiotropic nature of TNF-a, we
hypothesized that cell type-speciﬁc signaling at certain
stages of AD pathogenesis may differentially affect hall-
mark amyloid and Tau pathology and accompanying neu-
roinﬂammation. We previously demonstrated that long-term
nonselective abrogation of TNF-R expression in 3xTg-AD
mice results in signiﬁcant increases in AD-related path-
ology.24 In addition, long-term expression of TNF-a by
rAAV2 delivery in 3xTg-AD mice results in neuronal cell
loss, signifying that TNF-a is a potential contributor to
neuronal death in AD.13 To this end, age and disease stage
may alter neuronal TNF-R function, as demonstrated by
Patel and Brewer,39 who reported that in the presence of
Ab42, aging affects neuronal survival by changing TNF-R
expression. For example, neurons derived from “older”
mice were more vulnerable to Ab42 toxicity and were unable
to up-regulate TNF-RI and TNF-RII surface expression
compared with “middle-aged” neurons.39 Together, these
data suggest that microglial TNF-R signaling is likely
required at certain stages of disease to suppress pathology,
whereas other brain-resident cell populations, such as2293
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Figure 7 Neuronal TNF-R modulation resulted in a stage-dependent
alteration of endogenous TNF-a levels. Hippocampal protein homoge-
nates of 15-month-old (A) and 21-month-old (B) 3xTg-AD mice receiving
bilateral intrahippocampal injections at 2 and 12 months, respectively,
were subjected to TNF-a ELISA. One-way analysis of variance and Bonfer-
roni’s posttest were performed. Error bars indicate SEM. nZ 4. *P < 0.05,
**P < 0.001, and ***P < 0.0001.
Montgomery et alneurons, may be susceptible to Ab-induced toxicity with
intact TNF-R signaling. Therefore, to selectively study the
contribution of neuronal TNF-R signaling in AD, we
generated rAAV2-siRNA vectors to knock down receptor
expression in the early and late stages of disease. The
present results demonstrate that the designed TNF-R siRNA
DNA constructs are functional in knocking down their
assigned receptors in vitro and subsequent to rAAV2
packaging, capable of targeting neurons in the CA1 sub-
layer. Sustained inhibition of TNF-RII selectively in hip-
pocampal neurons increases the amyloid burden, elevates
Tau hyperphosphorylation, and diminishes Iba-1epositive
staining intensities of microglia during the later stages of
disease in 3xTg-AD mice.
The downstream signaling cascades assigned to TNF-RI
and TNF-RII are quite distinct, and execution of TNF-R
signaling depends on a variety of conditions, including the
cellular context, receptor conformation, and inﬂammatory
milieu. Several groups have elucidated divergent signaling
pathways for TNF-RI and TNF-RII in neurons. Yang et al40
reported that hippocampal neuron survival is unaffected in
culture in the absence of TNF-RI; however, neurons devoid
of TNF-RII are highly vulnerable to TNF-a at concentra-
tions as low as 100 pmol/L. Furthermore, ligation of TNF-RI2294and TNF-RII with TNF-a induces different cellular path-
ways where a classical NF-kB signaling cascade is favored
by TNF-RI engagement, whereas TNF-RII up-regulates p38
mitogen-activated protein kinase activity, suggesting that
altered TNF-R expression affects neuronal survival and is
likely a consequence of unique downstream signaling
pathways.40 Moreover, TNF-RII stimulation induces the
activation of alternative or noncanonical NFkB, which has
been shown to down-regulate proinﬂammatory cytokine
production.41,42 In the present study, we did not assess the
number of hippocampal neurons in vector-transduced mice.
Based on the aforementioned literature, it is possible that
the number of hippocampal neurons expressing siTNF-RII
would be reduced compared with siScr- or siTNF-RIe
infused cohorts because TNF-RI seems to elicit prosurvival
signals to neurons.
Evidence of the signaling dichotomy between TNF-RI
and TNF-RII also exists in the disease setting. In human
AD, TNF-RI protein and gene expression is increased
compared with TNF-RII, and TNF-R activation is abnormal
in AD brains where TNF-RI exhibits an increased binding
afﬁnity to TNF-a compared with nondemented control
patients.17,43 In preclinical studies, TNF-RI promotes Ab-
induced neuronal death, and in the APP23 mouse model,
deletion of TNF-RI reduced Ab plaque pathology, improved
spatial learning and memory, and decreased b-secretase
levels compared with littermate control mice.16,44 Similarly,
the present results show that silencing TNF-RII, but not
TNF-RI or TNF-RIþRII in combination, results in
dramatically enhanced 12F4-positive Ab plaque burden
(Figure 3, G, K, and L), insoluble Ab40/Ab42 levels
(Figure 4, G and H), and PHF-1 pathology (Figure 5). These
data suggest that unopposed neuron-speciﬁc TNF-RI
signaling during the later stages of disease leads to exac-
erbated pathology, and TNF-RII exerts protective responses
that may be required to counteract TNF-RIedriven signal
transduction.
Although there is a breadth of literature supporting the
development of therapies that inhibit TNF signaling in AD,
most studies contend that pan anti-TNF therapeutics are
optimal candidates for disease immunomodulation. Most of
these studies have not evaluated the impact of long-term use
of such agents or the cell- or stage-speciﬁc consequences of
such approaches. For example, Shi et al45 demonstrated that
transient intracerebroventricular infusion of inﬂiximab,
a monoclonal chimeric TNF-a antibody that binds soluble
and transmembrane forms of TNF-a, to double-transgenic
APP/PS1 mice reduced TNF-a levels, amyloid deposition,
and hyperphosphorylated Tau pathology. Although these
data are quite compelling, mice received the inﬂiximab
treatment only transiently for up to 14 days. More recently,
a novel thalidomide-derived TNF-aelowering agent, 3,60-
dithiothalidomide, which is more potent than thalidomide
itself, penetrates the blood-brain barrier, and posttranscrip-
tionally represses TNF-a, was administered over a 6-week
period to 17-month-old 3xTg-AD mice and was shown toajp.amjpathol.org - The American Journal of Pathology
TNF Receptor Ablation in 3xTg-AD Miceattenuate insoluble Ab plaque burden and memory and
learning deﬁcits as measured by the Morris water maze
task.46 This report is interesting because it examines TNF
inhibition in late-stage disease but, similar to other studies,
does not address the consequences of long-term and broad
silencing of TNF signaling. The present ﬁndings support
a conclusion that unopposed neuronal TNF-RI signaling,
when TNF-RII has been selectively down-regulated, leads
to a more severe course of AD pathogenesis. Hence, cell and
receptor typeespeciﬁc targeting of the TNF-Rs rather than
broad TNF intervention in advanced stages of disease may
represent a safer, albeit more complex, strategy by which to
impede disease progression.
The signiﬁcant reduction in Iba-1 intensities documented
in mice receiving rAAV2esiTNF-RII or rAAV2-siTNF-
RIþRII (Figure 6) strongly implicates a nonautonomous
role for neuronal TNF-RII signaling in AD whereby
neuronal TNF-RII may be indirectly affecting local micro-
glial function and/or activity. Given that neurons are able to
control microglial activity,36e38 it is plausible that unop-
posed TNF-RI signaling in neurons, when TNF-RII is
down-regulated, leads to elaboration of signals to local
microglia that impair functions such as microglial-mediated
clearance of Ab. There are a variety of surface molecules on
microglia that facilitate communication of regulatory signals
from neurons. For example, CD200 is constitutively
expressed on the neuronal surface as a glycoprotein that
directly communicates through cognate ligation with the
microglial CD200 receptor, which exerts inhibitory signals
to maintain microglia in a quiescent state. The inhibitory
role of CD200 was demonstrated in a facial nerve transec-
tion model where macrophages/microglial cells were in
higher numbers and displayed an activated phenotype in
CD200-deﬁcient mice.35 In addition, the CD47/integrin-
associated protein expressed by neurons interacts with
microglial SIRPa and is involved in phagocytic responses
regulated by Fc gamma and complement receptors.47 One of
the most studied microglial-neuronal interactions is the
fractalkine (CX3CL1) and fractalkine receptor (CX3CR1)
expressed on neurons and microglia, respectively. Although
the exact role of CX3CL1-CX3CR1 is not well understood,
it has been shown that removing CX3CR1 in hAAP-J20
mice worsens Tau pathology and performance in passive
avoidance and novel object recognition behaviors.48 TNF-
aeconverting enzyme (ADAM17), the enzyme involved in
proteolytic release of soluble TNF-a, has been associated
with CX3CL1 proteolysis from the cell surface. Because
TNF-RI preferentially signals via soluble TNF-a ligation, it
is possible that knocking down neuronal TNF-RII may lead
to an increase in local ADAM17 concentrations to act on
TNF-a and CX3CL1.49 Moreover, a variety of neurotrans-
mitters may modulate microglial cell activity. For example,
microglia express several glutamate receptors, including
group II metabotropic receptors, and stimulation of these
receptors has been shown to be associated with TNF-
RIemediated microglial neurotoxicity in a rat primaryThe American Journal of Pathology - ajp.amjpathol.orgmicroglia culture paradigm.50 Therefore, it is conceivable
that modulation of neuronal TNF-RI and TNF-RII receptor
expression via siRNA technology may affect microglia-
neuron communication and downstream microglial activa-
tion/function.
Although diminished microglial phagocytosis may unde-
rlie the enhanced Ab pathology observed when neuronal
TNF-RII expression is experimentally decreased, other not
necessarily mutually exclusive molecular and cellular
mechanisms may be involved. Increased Ab peptide load
may result from reduced Ab-degrading enzyme levels and/
or increased amyloid precursor protein (APP) processing
in neurons. Hickman et al51 reported that Ab-degrading
enzyme levels, including insulysin, neprilysin, and matrix
metallopeptidase 9, are signiﬁcantly decreased in 14-month-
old PSI-APP mice. This observation coincides with a
signiﬁcant increase in TNF-a transcript level at the same
age, suggesting that the up-regulation of TNF-a compro-
mises Ab-degrading pathways.51 This report supports the
possibility that unopposed TNF-RI signaling in neuronsmay
lead to the down-regulation of enzymes involved in Ab
degradation. Furthermore, studies have revealed that
b-secretase activity is augmented by TNF-RI as demon-
strated through use of a dominant-negative soluble TNF
inhibitor that primarily blocked TNF-RI transduction in
3xTg-AD mice. C-terminal APP fragments arising from b-
secretase activity were signiﬁcantly decreased in mice
receiving this inhibitor.22 Moreover, deletion of the TNF-RI
gene in APP23 mice was shown to abrogate Ab generation
by lowering b-secretase levels and activity, indicating that
TNF-RI facilitates amyloidogenic cleavage of APP.16
Whether the observed increases in pathogenic Ab peptide
and deposition detected in 21-month-old 3xTg-AD mice
receiving TNF-RII siRNA is a consequence of increased
TNF-RI and/or b-secretase activity is presently unknown.
However, the present data suggest that TNF-RI may not be
directly alteringAPP processing in the present study because
Ab levels in TNF-RI siRNAereceiving 3xTg-ADmicewere
comparable with those in aged-matched siScr control
counterparts (Figures 3 and 4).
In conclusion, we demonstrated that long-term knock-
down of TNF-RII in hippocampal neurons via rAAV2
vectoremediated siRNA delivery enhances amyloid- and
Tau-related pathologic features. The present work builds
on existing data cautioning against the long-term use of
pan antieTNF-a therapies for AD and emphasizes the
need for strategies that more selectively modulate TNF
signaling in speciﬁc cell types and at different stages of
disease. Moreover, these data provide a foundation for
understanding how neuron-speciﬁc targeting of TNF-R
signaling affects overall disease severity. Future studies
will focus on dissecting the TNF-mediated mechanisms
that lead to enhanced AD-associated pathology and on
assessing the effects of selective TNF signaling suppres-
sion in other brain-resident populations, including micro-
glia and astrocytes.2295
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